CLINICAL / SCIENTIFIC PRESENTATION AND PUBLICATION HIGHLIGHTS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE
39th Annual JP Morgan Healthcare Conference – Presentation
Webcast, CLICK HERE Download Presentation, CLICK HERE
Sutro Biopharma Presents at the American Society of Hematology (ASH) 2020 – Poster Presentation
Download the Presentation, Click Here
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular...
KOL Discussion of STRO-002 Data – PowerPoint Presentation & Audio Replay
To download the presentation, Click Here Audio Replay is assessable for 30 days to registrants, Click Here
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
- Responses observed in 32% (10/31) of evaluable patients treated at clinically active dose levels–including 1 CR, 3 cPRs and 6 uPRs - - Disease control rate at 12 weeks is 74% (23/31) and 10 patients remained on treatment - - Dose-expansion has been intiated to...
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
– Discussion of STRO-002 Data and Program Expansion at 5pm ET / 2pm PTon Dec. 3rd – SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences...
American Society of Hematology Conference 2020 – STRO-001 – Abstract
To view the abstract on ASH click here, ASH Website Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-cell Non-Hodgkin Lymphoma Nirav N. Shah1, Ahmad Mattour2, Leslie...
Sutro Biopharma Presents at World ADC 2020 – PowerPoint Presentation
To download the World ADC presentation by Arturo Molina, MD, MS, Chief Medical Officer, CLICK HERE To download the World ADC presentation by Trevor Hallam, Ph.D., Chief Scientific Officer, CLICK HERE To download the World ADC presentation by Shabbir Anik, Ph.D.,...
